Weiss Ratings Reiterates Sell (D-) Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “sell (d-)” rating restated by stock analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Other research analysts have also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 12th. Wall Street Zen upgraded shares of TScan Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 12th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, TScan Therapeutics has an average rating of “Moderate Buy” and an average price target of $7.80.

TScan Therapeutics Stock Up 0.5%

Shares of TScan Therapeutics stock opened at $1.98 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.06 and a quick ratio of 7.06. TScan Therapeutics has a 1 year low of $1.02 and a 1 year high of $6.23. The firm’s 50-day moving average is $1.81 and its two-hundred day moving average is $1.61. The stock has a market cap of $112.36 million, a price-to-earnings ratio of -1.82 and a beta of 0.99.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.28). TScan Therapeutics had a negative net margin of 1,964.88% and a negative return on equity of 63.33%. The company had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $1.31 million. As a group, research analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd acquired a new position in shares of TScan Therapeutics during the second quarter valued at about $26,000. Vanguard Personalized Indexing Management LLC acquired a new position in shares of TScan Therapeutics during the second quarter valued at about $29,000. Quadrature Capital Ltd acquired a new position in shares of TScan Therapeutics during the second quarter valued at about $33,000. Boothbay Fund Management LLC increased its holdings in shares of TScan Therapeutics by 50.0% during the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after acquiring an additional 8,121 shares in the last quarter. Finally, Hsbc Holdings PLC acquired a new position in shares of TScan Therapeutics during the first quarter valued at about $49,000. 82.83% of the stock is currently owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.